deltatrials
Unknown NCT00133900

Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving Chemotherapy

Circulating Tumor Cells and the Prediction of Overall Survival in Patients With Androgen Independent Prostate Cancer Entering Onto Chemotherapy

Sponsor: Immunicon

Conditions Hormone Refractory Prostate Cancer Prostate Cancer
Interventions Phlebotomy
Updated 10 times since 2017 Last updated: Jul 27, 2009 Started: Dec 31, 2004 Primary completion: Feb 28, 2009 Completion: Feb 28, 2009

A observational or N/A phase clinical study on Hormone Refractory Prostate Cancer and Prostate Cancer, this trial is ongoing. The trial is conducted by Immunicon and has accumulated 10 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown

    Status: Unknown Status → Unknown

  3. Dec 2021 — Jul 2024 [monthly]

    Unknown Status

  4. Jan 2021 — Dec 2021 [monthly]

    Unknown Status

  5. Nov 2020 — Jan 2021 [monthly]

    Unknown Status

▶ Show 5 earlier versions

  1. Jun 2018 — Nov 2020 [monthly]

    Unknown Status

  2. May 2018 — Jun 2018 [monthly]

    Unknown Status

  3. Apr 2018 — May 2018 [monthly]

    Unknown Status

    Phase: NA → None

  4. Aug 2017 — Apr 2018 [monthly]

    Unknown Status NA

  5. Jan 2017 — Aug 2017 [monthly]

    Unknown Status NA

    First recorded

Dec 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Immunicon
Data source: Immunicon

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Cleveland, United States